Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T15:56:26.769Z.
Calculation as of: 2026-10-06T15:56:26.769Z.
Quote observation: 2026-10-06T15:54:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e02887d9f7d553dead588493e3d1cc1cda6164751857f77264c258b40fe63259
PEG RATIO
N/A
Fulcrum Therapeutics, Inc.
Market Cap
$284.21M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | $284.21M | N/A |
| Indaptus Therapeutics, Inc. (INDP)vs › | $285.37M | N/A |
| Aurora Cannabis Inc. (ACB)vs › | $280.91M | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.68M | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $277.99M | N/A |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $290.50M | N/A |
| Standard BioTools Inc. (LAB)vs › | $289.76M | N/A |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $276.26M | N/A |
| Larimar Therapeutics, Inc. (LRMR)vs › | $296.13M | N/A |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $269.10M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
